Learning to Lead Through Observation and Passion

;

The Right Analysis for Financial Growth

The following firms and analysts currently cover Amarin Corporation:
Firm
Analyst
JP MorganJessica Fye
Goldman SachsPaul Choi
LeerinkRoanna Ruiz

Investor Contact

For corporate governance, analyst coverage, stock information, secretarial matters and other investor-related queries, please use the Contact form

About Amarin for Investors

Amarin is a leading cardiovascular health pharmaceutical company. As leaders, we apply science, research, passion and global knowledge to ensure we further our vision of stopping cardiovascular disease from being a leading cause of death. In order to achieve this vision, we take a strategic approach to management and financial responsibility.

Financial Information

Learn about Amarin's revenue, expenses, profit and loss, and the company's financial health.

Corporate Governance

Gain new insights into Amarin’s performance and corporate commitments.

Stock Information

View real-time stock prices and stock quotes.

About Amarin

A new paradigm in cardiovascular health management

Amarin Corporation is focused on a BOLD vision to stop cardiovascular disease from being a leading cause of death. Find out more about our vision and how we lead the way to better care for those with cardiovascular disease.

Science and Health

Passionate about cardiometabolic science and health

Learn more about the science underpinning our product and research & development efforts to advance innovation in cardiovascular disease.

News and Media

Press releases, news, updates and statements

From reports and reviews to partnerships and innovations, find out more about Amarin's latest news and stories as they stand in the press.

ALL-NP-00016 1/23
Amarin

You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information.

The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.

Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.

Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.

This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.

This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.

Information on this website may be revised without any prior notice.